PD-1/PD-L1 blockade in renal cell cancer

Kathryn E. Beckermann; Douglas B. Johnson; Jeffrey A. Sosman

doi:10.1080/1744666X.2016.1214575

PD-1/PD-L1 blockade in renal cell cancer

Kathryn E. Beckermann^*, Douglas B. Johnson, Jeffrey A. Sosman

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Review article › peer-review

26 Scopus citations

Abstract

Introduction: Immunotherapy using checkpoint inhibitors is providing significant benefit to patients with renal cell carcinoma (RCC), both in overall survival and tolerability of treatment. Given the recent approval of the first checkpoint inhibitor in RCC, this review discusses the background and clinical data for checkpoint inhibition in RCC. Areas covered: This review introduces and discusses the basic biologic mechanisms of checkpoint inhibitor function and focuses on the current evidence in clinical trials for the use of immunotherapy in RCC. Expert commentary: Immunotherapy has been a mainstay of therapy in RCC, but the recent approval of nivolumab with ORR of 25% and durable responses has provided a transformative new therapeutic option.

Original language	English (US)
Pages (from-to)	77-84
Number of pages	8
Journal	Expert Review of Clinical Immunology
Volume	13
Issue number	1
DOIs	https://doi.org/10.1080/1744666X.2016.1214575
State	Published - Jan 2 2017

Keywords

PD-1
PD-L1
Renal cell
atezolizumab
nivolumab
pembrolizumab

ASJC Scopus subject areas

Immunology and Allergy
Immunology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/1744666X.2016.1214575

Cite this

@article{6e86a797a9064b20b28246820d55242c,

title = "PD-1/PD-L1 blockade in renal cell cancer",

abstract = "Introduction: Immunotherapy using checkpoint inhibitors is providing significant benefit to patients with renal cell carcinoma (RCC), both in overall survival and tolerability of treatment. Given the recent approval of the first checkpoint inhibitor in RCC, this review discusses the background and clinical data for checkpoint inhibition in RCC. Areas covered: This review introduces and discusses the basic biologic mechanisms of checkpoint inhibitor function and focuses on the current evidence in clinical trials for the use of immunotherapy in RCC. Expert commentary: Immunotherapy has been a mainstay of therapy in RCC, but the recent approval of nivolumab with ORR of 25% and durable responses has provided a transformative new therapeutic option.",

keywords = "PD-1, PD-L1, Renal cell, atezolizumab, nivolumab, pembrolizumab",

author = "Beckermann, {Kathryn E.} and Johnson, {Douglas B.} and Sosman, {Jeffrey A.}",

note = "Publisher Copyright: {\textcopyright} 2016 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2017",

month = jan,

day = "2",

doi = "10.1080/1744666X.2016.1214575",

language = "English (US)",

volume = "13",

pages = "77--84",

journal = "Expert Review of Clinical Immunology",

issn = "1744-666X",

publisher = "Expert Reviews Ltd.",

number = "1",

}

TY - JOUR

T1 - PD-1/PD-L1 blockade in renal cell cancer

AU - Beckermann, Kathryn E.

AU - Johnson, Douglas B.

AU - Sosman, Jeffrey A.

PY - 2017/1/2

Y1 - 2017/1/2

N2 - Introduction: Immunotherapy using checkpoint inhibitors is providing significant benefit to patients with renal cell carcinoma (RCC), both in overall survival and tolerability of treatment. Given the recent approval of the first checkpoint inhibitor in RCC, this review discusses the background and clinical data for checkpoint inhibition in RCC. Areas covered: This review introduces and discusses the basic biologic mechanisms of checkpoint inhibitor function and focuses on the current evidence in clinical trials for the use of immunotherapy in RCC. Expert commentary: Immunotherapy has been a mainstay of therapy in RCC, but the recent approval of nivolumab with ORR of 25% and durable responses has provided a transformative new therapeutic option.

AB - Introduction: Immunotherapy using checkpoint inhibitors is providing significant benefit to patients with renal cell carcinoma (RCC), both in overall survival and tolerability of treatment. Given the recent approval of the first checkpoint inhibitor in RCC, this review discusses the background and clinical data for checkpoint inhibition in RCC. Areas covered: This review introduces and discusses the basic biologic mechanisms of checkpoint inhibitor function and focuses on the current evidence in clinical trials for the use of immunotherapy in RCC. Expert commentary: Immunotherapy has been a mainstay of therapy in RCC, but the recent approval of nivolumab with ORR of 25% and durable responses has provided a transformative new therapeutic option.

KW - PD-1

KW - PD-L1

KW - Renal cell

KW - atezolizumab

KW - nivolumab

KW - pembrolizumab

UR - http://www.scopus.com/inward/record.url?scp=85003881413&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85003881413&partnerID=8YFLogxK

U2 - 10.1080/1744666X.2016.1214575

DO - 10.1080/1744666X.2016.1214575

M3 - Review article

C2 - 27426025

AN - SCOPUS:85003881413

SN - 1744-666X

VL - 13

SP - 77

EP - 84

JO - Expert Review of Clinical Immunology

JF - Expert Review of Clinical Immunology

IS - 1

ER -

PD-1/PD-L1 blockade in renal cell cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this